TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17493498
Drug: Timely administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely administration of epinephrine
Study: 15361183
Drug: Adjuvant platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum chemotherapy
Study: 29108671
Drug: Metacognitive Reflection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Reflection and Insight Therapy (MERIT‐EP)
Study: 24853306
Drug: Adherence estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence estimated by pill count
Study: 24853306
Drug: Drug detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug detection (tenofovir diphosphate or emtricitabine triphosphate)
Study: 16389917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two approaches for adjustment
Study: 8556568
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms twice daily for 2 weeks
Study: 1971216
Drug: Dipipanone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipipanone (10 mg, oral)
Study: 1971216
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (443C81 and dipipanone)
Study: 28922226
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 80% oxygen
Study: 28922226
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 30% oxygen
Study: 24719126
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intracoronary abciximab and aspiration thrombectomy
Study: 19620075
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with morphine
Study: 15364776
Drug: Eptifibatide (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (IV bolus of 180 microg/kg body weight followed by continuous infusion of 2 microg/kg/min)
Study: 8078528
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group, 153 subjects)
Study: 8078528
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group)
Study: 10752815
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg/kg)
Study: 1249566
Drug: Stimulant drug
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant drug treatment (continued medication)
Study: 29441886
Drug: Mucosolvan® inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosolvan® inhalation in addition to conventional treatment
Study: 29441886
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only (Control)
Study: 29441886
Drug: Mucosolvan® inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosolvan® inhalation
Study: 25942443
Drug: Oral Valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Valganciclovir (VGCV) 900mg/day
Study: 25942443
Drug: Intravenous Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ganciclovir (GCV) 5mg/kg twice daily
Study: 22648280
Drug: Simulated soldier
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated soldier patrol (SP) at 42°C, 9% relative humidity for 2.5 hours with 400 mg ibuprofen
Study: 22648280
Drug: Simulated soldier
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated soldier patrol (SP) at room temperature for 2.5 hours with 400 mg ibuprofen
Study: 19090503
Drug: Ramelteon 16
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 16 mg nightly for 6 months
Study: 11253266
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of acetylsalicylic acid (ASA) daily
Study: 1588361
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment group (cholesterol reduction)
Study: 4002096
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 g of amoxicillin plus 1 g of probenecid (group 1)
Study: 4002096
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of amoxicillin twice a day for two days (group 2)
Study: 4002096
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg of amoxicillin three times a day for seven days (group 3)
Study: 31863755
Drug: Preventive protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive protocol consisting of intermittent ventilation of the right lung, restoration of bilateral ventilation, administration of mannitol before unclamping the aorta, and institution of mild hypothermia.
Study: 26712041
Drug: 0.5% AP736
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% AP736 formulation (test formulation; n = 24)
Study: 26712041
Drug: Vehicle formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle formulation (vehicle control; n = 24)
Study: 25399731
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and ARB (telmisartan)
Study: 19806411
Drug: Porous tantalum
Normalized name: tantalum
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous tantalum implant
Study: 18606612
Drug: cTnI levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: cTnI levels >0.01 microg/L
Study: 15748464
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U subcutaneously once weekly
Study: 10730720
Drug: Implant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant treatment (preference)
Study: 10730720
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (preference)
Study: 9187986
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (Group R, n = 20)
Study: 9187986
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose (Group G, n = 20)
Study: 2986424
Drug: hpGRF 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: hpGRF 100 micrograms/h infusion for 2 to 5 hours after a bolus of 50 micrograms hpGRF
Study: 30768188
Drug: Suboptimal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal care (delays in antibiotics)
Study: 29367653
Drug: Radiomic signature
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiomic signature derived from pre-therapy imaging using Intensity Direct and Neighbor Intensity Difference methods.
Study: 25336707
Drug: Atosiban (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (6.75 mg bolus, followed by 18 mg/h for 1 hour, then 6 mg/h for 2 hours)
Study: 12520569
Drug: Methylprednisolone 30
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 30 mg/kg 30 min before liver resection
Study: 29855069
Drug: Standard splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard splint therapy
Study: 21074013
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (buccal and sublingual)
Study: 17621572
Drug: Acapella device
Normalized name: Acmella oleracea flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acapella device used for airway clearance sessions at home twice daily during oral antibiotic therapy (n=10)
Study: 17621572
Drug: Usual airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual airway clearance sessions at home during oral antibiotic therapy (n=10)
Study: 8536677
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) at 900 mg/day or 1200 mg/day
Study: 23325919
Drug: l‐[1‐(13)C]threonine enterally
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐[1‐(13)C]threonine enterally or parenterally
Study: 23325919
Drug: l‐[1‐(13)C]lysine enterally
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐[1‐(13)C]lysine enterally or parenterally
Study: 21295881
Drug: Reirradiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reirradiation with various doses: 8 Gy single-dose, 5×3 Gy, 2×8 Gy, 5×4 Gy, single doses of 7 and 4 Gy.
Study: 21295881
Drug: Reirradiation (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reirradiation (various doses)
Study: 11148859
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Zoltrix)
Study: 9068312
Drug: One hour
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour amphotericin B infusion
Study: 9068312
Drug: Four hour
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four hour amphotericin B infusion
Study: 3010692
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg) with Propranolol
Study: 3010692
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg) with Atenolol
Study: 27217459
Drug: Nonmyeloablative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative chemotherapy with 1,200 cGy TBI
Study: 27217459
Drug: Nonmyeloablative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative chemotherapy without TBI
Study: 23526959
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment every three months for 21 months
Study: 23526959
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment every three months for 21 months
Study: 21169142
Drug: Fenoldopam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (0.2 μg/kg per minute)
Study: 21169142
Drug: Dopexamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (2 μg/kg per minute)
Study: 12363466
Drug: Combined passive
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals) and Hepatitis B vaccine (arm I)
Study: 12363466
Drug: Combined passive
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals)
Study: 10364782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard solution)
Study: 8529068
Drug: Dopamine 1
Normalized name: DOPamine 160 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 1 microgram/kg/min + Domperidone 30 mg
Study: 7022973
Drug: E7H7 (ethambutol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7H7 (ethambutol 15 mg/kg plus isoniazid 400 mg daily)
Study: 7022973
Drug: E2H2 (ethambutol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2H2 (ethambutol 45 mg/kg plus isoniazid 15 mg/kg twice a week)
Study: 7022973
Drug: E1H2 (ethambutol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1H2 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week plus isoniazid 15 mg/kg mid-way between the weekly doses)
Study: 7022973
Drug: E1H1 (ethambutol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1H1 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week)
Study: 29231503
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (acupuncture and western medication)
Study: 29231503
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (ribavirin granules 10 mg/kg a day, three times a day for 3 days)
Study: 21476029
Drug: Ileal pouch-rectal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ileal pouch-rectal muscle sheath anastomosis
Study: 18424129
Drug: (123)I‐mIBG positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: (123)I‐mIBG positive metastatic disease after four chemotherapy cycles
Study: 18424129
Drug: (123)I‐mIBG positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: (123)I‐mIBG positive metastatic disease after six chemotherapy cycles
Study: 11218246
Drug: Interferon-alpha2b (IFN-alpha2b)
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2b (IFN-alpha2b) treatment
Study: 9299856
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (group B)
Study: 9299856
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange and steroids without antiplatelet agents (group A)
Study: 9299856
Drug: Ticlopidine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine maintenance therapy (after disease remission)
Study: 8467430
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (100 mg, single oral dose)
Study: 30292589
Drug: Lixisenatide (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (10-20 μg daily subcutaneous injection)
Study: 22943927
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (fenofibrate and atorvastatin)
Study: 18812609
Drug: Intravenous CNTO
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CNTO 528
Study: 8909669
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (0.15 mg/kg)
Study: 2483556
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation and combination of bleomycin and 5-fluorouracil (5-FU)
Study: 28225506
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg IV ibuprofen in 100 mL saline
Study: 26188456
Drug: Increased social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased social control treatment (participants played in randomly assigned pairs of two)
Study: 26188456
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment (subjects rolled a die in private)
Study: 23004005
Drug: Peironimev‐plus/oral/one tablet‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peironimev‐plus/oral/one tablet‐daily + Verapamil injection (peri‐lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week for 6 months
Study: 23004005
Drug: Verapamil injection
Normalized name: verapamil Injection
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil injection (peri‐lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week for 6 months
Study: 21940760
Drug: CX717 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX717 1000 mg
Study: 8080670
Drug: Dipyrone 1
Normalized name: dipyrone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1 g every 8 h (n = 41)
Study: 8080670
Drug: Dipyrone 2
Normalized name: dipyrone 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2 g every 8 h (n = 38)
Study: 8080670
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg every 4 h (n = 42)
Study: 8080670
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g or 2 g)
Study: 2583144
Drug: All beverage
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beverage treatments
Study: 338198
Drug: Elevated levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated levels of antibodies to milk proteins in infants fed cow milk.
Study: 28526210
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg daily for 48 weeks
Study: 28526210
Drug: As-needed β2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed β2-agonists
Study: 22503005
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml increase in dead space through a custom designed full face mask
Study: 16299869
Drug: Videotape and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape and brochure with practical skills for self-control and treatment
Study: 12571210
Drug: Radioiodine (RAI)
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine (RAI) administered at a dose of 12,580 kBq/mL of nodular volume (NV)
Study: 12571210
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (PEI) followed by radioiodine (RAI)
Study: 10353578
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of budesonide Turbuhaler administered twice daily
Study: 10353578
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of budesonide Turbuhaler administered twice daily
Study: 8575948
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (21 mg to 14 mg to 7 mg, each for 30 days)
Study: 1680600
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg kg‐1 i.v.) during exercise
Study: 6989437
Drug: Advice on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice on dietary reduction of plasma cholesterol, smoking cessation, regular exercise, reduced energy intake for overweight, and hypertension treatment.
Study: 7964913
Drug: Intranasal sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal sumatriptan 20 mg
Study: 3105506
Drug: Transdermal Trinitrin
Normalized name: Trinitrine
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Trinitrin (10 mg per 24 hours)
Study: 30863047
Drug: Glycopyrrolate (GLY)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (GLY) 15.6 µg twice daily
Study: 15836660
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin + placebo alpha‐tocopherol
Study: 15836660
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU alpha‐tocopherol + placebo atorvastatin
Study: 15836660
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin + 800 IU alpha‐tocopherol
Study: 15836660
Drug: placebo atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo atorvastatin + placebo alpha‐tocopherol
Study: 11888030
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of risedronate sodium
Study: 30396440
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to bacteria through cultural practices (e.g., consumption of unboiled milk, access to water sources)
Study: 24568360
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure treatment for four weeks
Study: 24568360
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual for four weeks
Study: 20188795
Drug: L/S' genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/S' genotype
Study: 12397459
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine therapy (at least 2.96 GBq iodine-131, maximal administered activity 22.3 GBq)
Study: 12397459
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine therapy
Study: 15490777
Drug: Bonding agent/composite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonding agent/composite combination (Prime & Bond 2.1/PrismaTPH)
Study: 7646610
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block with 10 mL of 1% mepivacaine hydrochloride solution (n = 87)
Study: 4719668
Drug: Alum-precipitated M
Normalized name: Precipitated Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-precipitated M protein vaccine
Study: 105114
Drug: 0.1 unit/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 unit/kg regular insulin given intramuscularly every two hours
Study: 105114
Drug: 1.0 unit/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 unit/kg regular insulin given half subcutaneously and half intravenously every 4 hours